ImmuCell

ICCC · NASDAQ

$10.45−$0.06 (−0.57%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.51

Latest news

NewsAug 14, 11:51 AM ET
ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript
NewsAug 13, 4:06 PM ET
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
Press releaseAug 13, 4:05 PM ETGlobe Newswire
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
NewsMay 14, 4:07 PM ET
ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY
Press releaseMay 14, 4:05 PM ETGlobe Newswire
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
NewsMar 4, 4:08 PM ET
ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY
Press releaseMar 4, 4:05 PM ETGlobe Newswire
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
NewsMar 4, 6:11 AM ET
Earnings Scheduled For March 4, 2026
Press releaseJan 8, 4:05 PM ETGlobe Newswire
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
NewsDec 29, 8:15 AM ET
ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business
NewsDec 26, 9:31 AM ETVandana Singh
ImmuCell Puts Re-Tain On Pause After FDA Letter
Press releaseDec 24, 1:05 PM ETGlobe Newswire
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
Press releaseNov 13, 4:05 PM ETGlobe Newswire
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
Press releaseNov 4, 4:05 PM ETGlobe Newswire
ImmuCell Announces Onboarding of New CEO and Related Management Changes
Press releaseOct 7, 4:05 PM ETGlobe Newswire
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
Press releaseSep 29, 4:05 PM ETGlobe Newswire
ImmuCell Announces Selection of its Next President and CEO
NewsMay 14, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsJul 10, 3:25 AM ETAvi Kapoor
PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript

ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

Earnings Scheduled For May 14, 2026

ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

Earnings Scheduled For March 4, 2026

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business

ImmuCell Puts Re-Tain On Pause After FDA Letter

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

ImmuCell Announces Onboarding of New CEO and Related Management Changes

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

ImmuCell Announces Selection of its Next President and CEO

12 Health Care Stocks Moving In Wednesday's After-Market Session

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday